PURPOSE: To evaluate the wavefront-optimized algorithm of the Allegretto Wave Eye-Q (Wavelight AG) 400-Hz excimer laser platform. METHODS: Three hundred three eyes of 303 patients treated with advanced surface ablation were evaluated prospectively. Topical mitomycin C (MMC) was used when ablation was ≥80 μm. Efficacy, safety, and predictability at 12 months were quantified with subjective refraction, visual acuity (logMAR), and slit-lamp examination. RESULTS: Mean postoperative uncorrected distance visual acuity (UDVA) was 20/20.5 (0.01±0.05 logMAR). Postoperative UDVA was equal or better than preoperative corrected distance visual acuity (CDVA) in 94.7% of eyes. Efficacy index was 1.05. Corrected distance visual acuity was maintained (93.7%) or improved (5.9%) in 99.6% of treated eyes. No patient lost ≥2 lines. Safety index was 1.05. Haze at 12 months was grade ≥0.5 in 98% of treated eyes and grade ≤1 in 100% of treated eyes. Mean postoperative manifest refraction spherical equivalent (MRSE) was -0.03±0.15 diopters (D). Postoperative MRSE was within ±0.50 D in 99% of eyes. Overcorrection was documented in 0.66% and undercorrection in 0.33% of eyes. CONCLUSIONS: The wavefront-optimized algorithm of the Allegretto Wave Eye-Q excimer laser platform showed good efficacy, safety, and predictability in advanced surface ablation, with or without MMC intraoperative use.

Wavefront-optimized surface ablation with the Allegretto Wave Eye-Q excimer laser platform : 12-Month visual and refractive results / C. Gambato, A.G. Catania, S. Vujosevic, E. Midena. - In: JOURNAL OF REFRACTIVE SURGERY. - ISSN 1081-597X. - 27:11(2011 Nov), pp. 792-795. [10.3928/1081597X-20110407-01]

Wavefront-optimized surface ablation with the Allegretto Wave Eye-Q excimer laser platform : 12-Month visual and refractive results

S. Vujosevic
Penultimo
;
2011

Abstract

PURPOSE: To evaluate the wavefront-optimized algorithm of the Allegretto Wave Eye-Q (Wavelight AG) 400-Hz excimer laser platform. METHODS: Three hundred three eyes of 303 patients treated with advanced surface ablation were evaluated prospectively. Topical mitomycin C (MMC) was used when ablation was ≥80 μm. Efficacy, safety, and predictability at 12 months were quantified with subjective refraction, visual acuity (logMAR), and slit-lamp examination. RESULTS: Mean postoperative uncorrected distance visual acuity (UDVA) was 20/20.5 (0.01±0.05 logMAR). Postoperative UDVA was equal or better than preoperative corrected distance visual acuity (CDVA) in 94.7% of eyes. Efficacy index was 1.05. Corrected distance visual acuity was maintained (93.7%) or improved (5.9%) in 99.6% of treated eyes. No patient lost ≥2 lines. Safety index was 1.05. Haze at 12 months was grade ≥0.5 in 98% of treated eyes and grade ≤1 in 100% of treated eyes. Mean postoperative manifest refraction spherical equivalent (MRSE) was -0.03±0.15 diopters (D). Postoperative MRSE was within ±0.50 D in 99% of eyes. Overcorrection was documented in 0.66% and undercorrection in 0.33% of eyes. CONCLUSIONS: The wavefront-optimized algorithm of the Allegretto Wave Eye-Q excimer laser platform showed good efficacy, safety, and predictability in advanced surface ablation, with or without MMC intraoperative use.
Adult; Algorithms; Alkylating Agents; Astigmatism; Cornea; Female; Humans; Lasers, Excimer; Male; Middle Aged; Mitomycin; Myopia; Prospective Studies; Refraction, Ocular; Treatment Outcome; Visual Acuity; Young Adult
Settore MED/30 - Malattie Apparato Visivo
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/884530
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 12
social impact